Commented Owen Roberts.
We’re happy with the confidence and support shown by our investors to summarize this financing circular and delighted to really have the OETF join us, commented Owen Roberts, Chief Financial Officer of Affinium Pharmaceuticals. This funding will fully fund Affinium’s next two key development goals, the completion of a phase 2 trial for our oral tablet and stage 1 trials of our new IV formulations said Dr. Barry Hafkin, Chief Medical Officer of Affinium Pharmaceuticals. Affinium will initiate shortly a stage 2 clinical study of oral AFN-1252 in acute bacterial epidermis and skin structure attacks.. Affinium closes $15 million financing round Affinium Pharmaceuticals announced today the closing of its $15 million financing.The ability not merely to examine, but also to approve a treatment plan is a function not available with any additional tablet-based radiation oncology application available today. ‘I am confident that PlanTouch can make our department better by enabling us to speed up enough time between consult, planning and initiation of treatment, which will, subsequently, enable us to take care of more individuals,’ said Donald B. Fuller, M.D., radiation oncologist, CyberKnife Centers of NORTH PARK. ‘The technology also offers the potential to facilitate and improve timely communication about a patient’s treatment solution among all treating doctors, helping us ensure that individuals receive the best possible cancer care.’ Related StoriesNew guidance declaration on palliative treatment to be offered at 2015 Palliative Treatment in Oncology SymposiumFDA approves LONSURF for treatment of patients with metastatic colorectal cancerLilly, ImaginAb partner to review potential novel T-cell-based immuno-oncology therapiesUnlike developed radiation treatment software previously, Accuray’s PlanTouch is specifically designed for use on the iPad.